Press Releases

October 20, 2017

Afimmune receives a patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
March 29, 2017

Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

Dublin, Ireland, 29th March 2017: Afimmune, a privately held biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted fast track […]
September 6, 2016

Afimmune Will Present Data on Oral DS102 at the European Respiratory Society

Dublin, Ireland, 6th September 2016: Afimmune will today present an abstract entitled ”DS102: a bioactive lipid for the treatment of chronic pulmonary disorders” at the European […]
May 23, 2016

Afimmune announces DS102 will be developed for pulmonary disorders in addition to NASH

Dublin, Ireland, 23rd May, 2016: Afimmune today announced plans to develop its anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive pulmonary disease (COPD) patients as well […]
April 14, 2016

Afimmune presents late-breaking news abstract on DS102 at the European Association for the Study of the Liver (EASL) International Liver Congress

Dublin, Ireland, 14th April 2016: Afimmune is today presenting a late-breaking news abstract at the annual meeting of the EASL International Liver Congress in Barcelona, Spain […]
January 5, 2016

Positive Pre-Clinical Results for Non-Alcoholic Steatohepatitis (NASH)

Afimmune today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis (NASH). DS102 […]
December 18, 2015

Afimmune obtains a granted patent covering the use of DS102 to treat fatty liver disorders

Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, announced today that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 […]
December 18, 2015

Afimmune announces successful completion of a Phase I safety study with bioactive lipid DS102 which is targeting NASH and IPF

Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]